Products
Sell Partner sirolimus-eluting coronary stent system
Reliable choice, forever partner
PatnerTM Sirolimus-eluting Coronary Stent System is one of the most widely used DES in interventional cardiolgy in China. Introduced from 2005, more than 200, 000 Partner stents have been implanted in patients and extremely excellent clinical results have been achieved.
The successful delivery of safety and efficacy through the combination of a proven drug and a reliable polymer
A Proven Drug
Maximum DES Efficacy
1. Over 5 years of proven clinical application experience
2. Effective anti-restenosis and anti-inlammatory properties
A Reliable Polymer
Long-term safety
1. Advanced polymer-coating technology provides optimally controlled release of sirolimus that efficaciously inhibits intimal hyperplasia and restenosis.
2. PBMA/PEVA coating is a widely used biocompatible coating that provides an ideally controlled drug release
3. Only 6 micrometer thickness of polymer, thinner coating increases deliverability of stent
Advanced Stent Design
High confidence delivery
1. Proprietary DOUBLE-HELIX stent structure is engineered for outstanding flexibility and conformability.
2. Optimal thickness of stent strut provides favorable balance between radial strength and deliverability
3. The unique 36 mm length makes it easy to achieve full coverage of long lesion.
Technical Parameters
Stent Material 316 LVM Stainless Steel
Strut Design Open cell
Metall to Artery Ratio 15%
Recoil <2%
Shortening <1%
Strut Thickness 0.0045"
Delivery System
Catheter Design Rapid Exchange
Balloon Compliance Semi-compliant
Nominal Pressure 8 atm
Rated Burst Pressure 2.5-3.5mm 16 atm
4.0mm 14 atm
Distal Shaft (outer diameter) 2.8 Fr
Proximal Shaft (outer diameter) 2.3 Fr
Crossing Profile (3.0 mm diameter) 1.0 mm
Usable Catheter Length 135 cm
Minimum Guiding Catheter Compatibility 6 Fr / 0.070" I.D.
Guidewire Compatible 0.014"
Specifications:
Diameter(mm): 2.5,2.75,3.0,3.5,4.0
Length(mm):12,15,18,21,24,29,36
Supported by clinical data
FIM clinical study
Multi-center, randomized First In Man Trial to demonstrate safety and efficacy of Partner DES in coronary De Novo lesions. N=81.
Primary Endpoint: In-segment Late Loss at 6 months
Conclusions:
? Excellent device (100%) and procedure (100%) success.
? Low in-segment late loss (0.03±0.14 mm).
? No incidence of stent thrombosis.,
Partner Retrospective clinical study
Multi-center "real world" clinical study. N=1352.
Primary Endpoint: MACE at 12 month.
Conclusions:
? Low MACE rate (3.62%).
? Low revascularization rate (2.14%).
? Low stent thrombosis (0.66%).
Delivery Lead Time: 2 week(s)
View All Products posted by
Lepu Medical Technology(Beijing)Co.,Ltd
Keywords: coronary stent, stent, cardiovascular, cardiac, interventional
Tags: #coronary stent, #stent, #cardiovascular, #cardiac, #interventional
